American Century Companies Inc. Invests $18.18 Million in GoodRx Holdings, Inc. (NASDAQ:GDRX)

American Century Companies Inc. acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,331,151 shares of the company’s stock, valued at approximately $18,183,000. American Century Companies Inc. owned 0.62% of GoodRx at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GDRX. Rubric Capital Management LP acquired a new position in GoodRx during the fourth quarter valued at approximately $39,348,000. Picton Mahoney Asset Management acquired a new position in GoodRx during the first quarter valued at approximately $3,467,000. Rip Road Capital Partners LP boosted its position in GoodRx by 25.8% during the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock valued at $11,814,000 after purchasing an additional 361,294 shares during the last quarter. GSA Capital Partners LLP acquired a new position in GoodRx during the first quarter valued at approximately $1,638,000. Finally, Mckinley Capital Management LLC acquired a new position in GoodRx during the first quarter valued at approximately $1,280,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.17% of the company’s stock.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $6.91 on Friday. The firm has a market cap of $2.59 billion, a P/E ratio of -691.00, a price-to-earnings-growth ratio of 3.55 and a beta of 1.38. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. GoodRx Holdings, Inc. has a 1-year low of $4.14 and a 1-year high of $9.26. The business’s 50 day moving average is $7.97 and its 200-day moving average is $7.59.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The firm had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. During the same quarter last year, the business posted $0.02 EPS. GoodRx’s revenue for the quarter was up 5.7% on a year-over-year basis. Equities research analysts predict that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

GDRX has been the subject of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research note on Friday, August 9th. Morgan Stanley upped their price objective on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. Citigroup dropped their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, UBS Group dropped their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and an average price target of $9.36.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.